FI3757126T3 - Menetelmä nivelreuman hoitamiseksi il-17-antagonistien avulla - Google Patents

Menetelmä nivelreuman hoitamiseksi il-17-antagonistien avulla

Info

Publication number
FI3757126T3
FI3757126T3 FIEP20187001.1T FI20187001T FI3757126T3 FI 3757126 T3 FI3757126 T3 FI 3757126T3 FI 20187001 T FI20187001 T FI 20187001T FI 3757126 T3 FI3757126 T3 FI 3757126T3
Authority
FI
Finland
Prior art keywords
psoriatic arthritis
antagonists
methods
treating psoriatic
secukinumab
Prior art date
Application number
FIEP20187001.1T
Other languages
English (en)
Finnish (fi)
Inventor
Shepard Mpofu
Hanno Richards
Karthinathan Thangavelu
Matthias Machacek
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44906168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3757126(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of FI3757126T3 publication Critical patent/FI3757126T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
FIEP20187001.1T 2010-11-05 2011-11-04 Menetelmä nivelreuman hoitamiseksi il-17-antagonistien avulla FI3757126T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41053310P 2010-11-05 2010-11-05

Publications (1)

Publication Number Publication Date
FI3757126T3 true FI3757126T3 (fi) 2025-10-12

Family

ID=44906168

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20187001.1T FI3757126T3 (fi) 2010-11-05 2011-11-04 Menetelmä nivelreuman hoitamiseksi il-17-antagonistien avulla

Country Status (30)

Country Link
US (10) US9744234B2 (cg-RX-API-DMAC7.html)
EP (6) EP3542820A1 (cg-RX-API-DMAC7.html)
JP (8) JP2014503482A (cg-RX-API-DMAC7.html)
KR (5) KR20150020734A (cg-RX-API-DMAC7.html)
CN (2) CN104800844A (cg-RX-API-DMAC7.html)
AU (1) AU2011325134B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013011176A2 (cg-RX-API-DMAC7.html)
CA (2) CA2813849C (cg-RX-API-DMAC7.html)
CL (1) CL2013001213A1 (cg-RX-API-DMAC7.html)
CY (1) CY1121802T1 (cg-RX-API-DMAC7.html)
DE (1) DE20187001T1 (cg-RX-API-DMAC7.html)
DK (2) DK3111954T3 (cg-RX-API-DMAC7.html)
ES (3) ES2804624T1 (cg-RX-API-DMAC7.html)
FI (1) FI3757126T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20251174T1 (cg-RX-API-DMAC7.html)
HU (1) HUE044038T2 (cg-RX-API-DMAC7.html)
IL (4) IL311014A (cg-RX-API-DMAC7.html)
LT (2) LT3757126T (cg-RX-API-DMAC7.html)
MA (1) MA34647B1 (cg-RX-API-DMAC7.html)
MX (1) MX362591B (cg-RX-API-DMAC7.html)
PH (1) PH12013500890A1 (cg-RX-API-DMAC7.html)
PL (1) PL3111954T3 (cg-RX-API-DMAC7.html)
PT (2) PT3757126T (cg-RX-API-DMAC7.html)
RS (1) RS67377B1 (cg-RX-API-DMAC7.html)
RU (1) RU2582937C2 (cg-RX-API-DMAC7.html)
SG (2) SG189138A1 (cg-RX-API-DMAC7.html)
SI (1) SI3111954T1 (cg-RX-API-DMAC7.html)
TR (1) TR201909531T4 (cg-RX-API-DMAC7.html)
TW (3) TWI604851B (cg-RX-API-DMAC7.html)
WO (1) WO2012059598A2 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG185354A1 (en) 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
CN104800844A (zh) 2010-11-05 2015-07-29 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2771022B1 (en) 2011-10-11 2020-07-01 Viela Bio, Inc. Cd40l-specific tn3-derived scaffolds and methods of use thereof
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
CA2928317A1 (en) * 2013-10-22 2015-04-30 Novimmune S.A. Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers
CN105916883B (zh) * 2014-01-28 2019-12-03 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
PL3142751T3 (pl) 2014-05-13 2019-12-31 Medimmune Limited Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CA3198322A1 (en) 2014-05-15 2015-11-19 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
FR3021976B1 (fr) * 2014-06-06 2018-11-02 Hospices Civils De Lyon Marqueur biologique permettant d'evaluer le niveau pro-inflammatoire dependant de la contribution fonctionnelle de l'il-17 chez un individu
WO2015191760A2 (en) * 2014-06-10 2015-12-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
NL2013007B1 (en) * 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
DK3191120T3 (da) * 2014-09-10 2024-07-15 Novartis Ag Anvendelse af IL-17-antagonister for at hæmme progressionen af strukturel skade hos patienter med psoriasisgigt
AU2015336101A1 (en) * 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
ES3000557T3 (en) 2015-03-02 2025-02-28 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
WO2017068472A1 (en) * 2015-10-19 2017-04-27 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
JP2019534240A (ja) * 2016-08-23 2019-11-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法
US20210179702A1 (en) * 2017-11-02 2021-06-17 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
CA3098277A1 (en) * 2018-05-09 2019-11-14 Novartis Ag Use of canakinumab
KR20210110287A (ko) * 2018-09-26 2021-09-07 비엘라 바이오, 인크. Cd40l 길항제 및 이의 용도
CA3125236A1 (en) * 2019-01-22 2020-07-30 F. Hoffmann-La Roche Ag Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
KR102169901B1 (ko) * 2019-05-17 2020-10-26 연세대학교 산학협력단 Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
MX2022001607A (es) * 2019-08-05 2022-03-11 Evelo Biosciences Inc Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola.
KR20220066318A (ko) 2019-09-20 2022-05-24 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용한 자가면역 질환의 치료 방법
KR20220103141A (ko) 2019-11-19 2022-07-21 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용하여 루푸스 신장염을 치료하는 방법
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
WO2021146850A1 (en) * 2020-01-20 2021-07-29 Tsinghua University A critical role of febrile temperature in regulating interleukin (il) -17 producing cells via smad4
EP4251197A4 (en) * 2020-11-25 2024-10-23 Dr. Reddy's Laboratories Ltd. STABLE THERAPEUTIC PROTEIN FORMULATION AND METHODS OF MANUFACTURE THEREOF
WO2022144023A1 (zh) * 2021-01-04 2022-07-07 江苏恒瑞医药股份有限公司 抗il-17抗体治疗自身免疫性疾病和炎症的方法
TW202246329A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
KR102339377B1 (ko) * 2021-03-29 2021-12-13 김지혜 사용자 맞춤형 문화 예술 컨텐츠 제공 방법 및 장치
CN117500834A (zh) * 2021-06-21 2024-02-02 百时美施贵宝公司 使用蔗糖、甘露糖醇和甘氨酸来减少高浓度冻干生物制剂药物产品的重构时间
CN114306594A (zh) * 2021-12-21 2022-04-12 华中科技大学同济医学院附属协和医院 地舒单抗在制备治疗膝关节骨性关节炎的药物中的应用
EP4654999A1 (en) 2023-01-27 2025-12-03 Fresenius Kabi Deutschland GmbH Biopharmaceutical composition
EP4406553A1 (en) 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
WO2025071335A1 (ko) * 2023-09-27 2025-04-03 삼성바이오에피스 주식회사 항-il-17 항체의 안정한 액상 제형

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US5250442A (en) * 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
CN101469329B (zh) 1998-11-27 2012-10-24 达尔文发现有限公司 增加骨矿化的组合物和方法
JP4159682B2 (ja) 1998-12-22 2008-10-01 株式会社クラレ 止血材
DE60235013D1 (de) 2001-07-25 2010-02-25 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
MXPA04004459A (es) 2001-11-09 2005-05-16 Johnson & Johnson Composiciones liofilizadas de anticuerpo monoclonal.
EP1575481A4 (en) 2002-03-01 2010-01-06 Celltech R & D Inc PROCESS FOR INCREASING OR REDUCING THE BONE DENSITY
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US6974701B2 (en) 2003-03-21 2005-12-13 Hemovations, Llc Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same
CN1835974A (zh) 2003-06-16 2006-09-20 细胞技术研究与发展公司 对硬化素特异的抗体和用于增加骨矿化的方法
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8039642B2 (en) 2003-12-09 2011-10-18 Life Technologies Corporation Pyrenyloxysulfonic acid fluorescent agents
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP3936365B2 (ja) 2004-09-14 2007-06-27 ソニーケミカル＆インフォメーションデバイス株式会社 機能素子実装モジュール及びその製造方法
AR054233A1 (es) 2005-03-08 2007-06-13 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos igg2
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP1957474A4 (en) 2005-11-04 2011-08-24 Harvard College SYNTHESIS OF FTSZ HEMMERN
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
CN101374864A (zh) 2006-01-31 2009-02-25 诺瓦提斯公司 用于靶向癌症的il-17拮抗性抗体
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
CN101627055A (zh) 2006-09-05 2010-01-13 梅达雷克斯公司 骨形成蛋白及其受体的抗体以及它们的使用方法
WO2008029908A1 (fr) 2006-09-07 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Préparation pharmaceutique lyophilisée stable comprenant un anticorps
CN101541833B (zh) * 2006-10-02 2014-01-29 麒麟-安姆根有限公司 Il-17受体a抗原结合蛋白质
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP2097450A2 (en) 2006-11-10 2009-09-09 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2094731A2 (en) 2006-11-10 2009-09-02 UCB Pharma S.A. Anti human sclerostin antibodies
JP2010526766A (ja) 2007-02-02 2010-08-05 ノバルティス アーゲー 骨関連障害を処置するためのスクレロスチン結合パートナーのモジュレーター
PT2131860E (pt) 2007-03-20 2014-03-04 Lilly Co Eli Anticorpos antiesclerostina
EP2136839A4 (en) 2007-03-22 2010-04-07 Imclone Llc STABLE ANTIBODY FORMULATIONS
EP2068923A4 (en) * 2007-03-30 2010-11-24 Medimmune Llc ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
US20100239590A1 (en) * 2007-06-20 2010-09-23 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
US7720605B2 (en) 2007-06-22 2010-05-18 Weyerhaeuser Nr Company Identifying vegetation attributes from LiDAR data
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
US20110044978A1 (en) 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20090301682A1 (en) 2008-06-05 2009-12-10 Baker Hughes Incorporated Casting furnace method and apparatus
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
WO2010034443A1 (en) 2008-09-29 2010-04-01 F. Hoffmann-La Roche Ag Antibodies against human il 17 and uses thereof
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
FR2938547B1 (fr) 2008-11-14 2012-11-16 Total Raffinage Marketing Liant synthetique clair
US20110256130A1 (en) 2008-12-01 2011-10-20 Joshua Robert Schultz Methods of treating inflammatory disorders
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
LT2625199T (lt) 2010-10-08 2018-03-12 Novartis Ag Psoriazės gydymo būdai panaudojant il-17 antagonistus
CN104800844A (zh) 2010-11-05 2015-07-29 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法
WO2012082573A1 (en) * 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
US20150064193A1 (en) 2011-11-21 2015-03-05 Novartis Ag Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles
US20150125462A1 (en) 2012-04-20 2015-05-07 Stephan Bek Methods of treating ankylosing spondylitis using il-17 antagonists
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2017068472A1 (en) 2015-10-19 2017-04-27 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
US11280479B2 (en) 2017-10-18 2022-03-22 The Sloan Company Sign box light module

Also Published As

Publication number Publication date
RU2582937C2 (ru) 2016-04-27
CN103189074A (zh) 2013-07-03
DE20187001T1 (de) 2021-04-01
TW201726170A (zh) 2017-08-01
ES3030036T3 (en) 2025-06-26
PT3111954T (pt) 2019-07-10
EP3912640B1 (en) 2025-03-05
EP3757126B1 (en) 2025-09-03
MX2013005060A (es) 2013-06-28
KR20180019247A (ko) 2018-02-23
RU2013125775A (ru) 2014-12-10
CY1121802T1 (el) 2020-07-31
HRP20251174T1 (hr) 2025-11-21
AU2011325134A1 (en) 2013-04-04
CA2813849C (en) 2021-06-15
WO2012059598A2 (en) 2012-05-10
DK3757126T3 (da) 2025-09-29
US12465635B2 (en) 2025-11-11
US20250205332A1 (en) 2025-06-26
JP2018065826A (ja) 2018-04-26
CA3116725A1 (en) 2012-05-10
TWI604851B (zh) 2017-11-11
CL2013001213A1 (es) 2014-03-28
TW201517917A (zh) 2015-05-16
TWI616204B (zh) 2018-03-01
PT3757126T (pt) 2025-11-13
CA2813849A1 (en) 2012-05-10
EP3111954B1 (en) 2019-04-03
US20220193234A1 (en) 2022-06-23
US10363307B2 (en) 2019-07-30
TR201909531T4 (tr) 2019-07-22
IL225309A0 (en) 2013-06-27
IL225309B (en) 2021-05-31
JP2019142912A (ja) 2019-08-29
US20190307880A1 (en) 2019-10-10
US20200276305A1 (en) 2020-09-03
JP6250109B2 (ja) 2017-12-20
CA3116725C (en) 2023-10-24
JP6515168B2 (ja) 2019-05-15
RS67377B1 (sr) 2025-11-28
MX362591B (es) 2019-01-25
EP3111954A1 (en) 2017-01-04
PH12013500890A1 (en) 2013-07-01
LT3111954T (lt) 2019-07-10
US20210177966A1 (en) 2021-06-17
JP2014503482A (ja) 2014-02-13
KR20160067984A (ko) 2016-06-14
US20180008706A1 (en) 2018-01-11
JP2023109910A (ja) 2023-08-08
HRP20191162T1 (hr) 2019-10-04
EP3542820A1 (en) 2019-09-25
US20210128726A1 (en) 2021-05-06
WO2012059598A3 (en) 2012-09-27
EP3912640A1 (en) 2021-11-24
KR20180129991A (ko) 2018-12-05
TW201306864A (zh) 2013-02-16
SI3111954T1 (sl) 2019-08-30
US9744234B2 (en) 2017-08-29
KR20140008305A (ko) 2014-01-21
ES2804624T1 (es) 2021-02-08
HUE044038T2 (hu) 2019-09-30
JP2016065094A (ja) 2016-04-28
JP2017002064A (ja) 2017-01-05
IL262559B (en) 2022-06-01
LT3757126T (lt) 2025-12-10
EP2635303A2 (en) 2013-09-11
TWI618543B (zh) 2018-03-21
JP2021104995A (ja) 2021-07-26
IL311014A (en) 2024-04-01
MA34647B1 (fr) 2013-11-02
IL282625A (en) 2021-06-30
JP2025102772A (ja) 2025-07-08
US11534491B2 (en) 2022-12-27
US20130209480A1 (en) 2013-08-15
US20230346926A1 (en) 2023-11-02
EP4116325A1 (en) 2023-01-11
EP3757126A1 (en) 2020-12-30
ES2733712T3 (es) 2019-12-02
SG189138A1 (en) 2013-05-31
SG10201505624VA (en) 2015-09-29
DK3111954T3 (da) 2019-07-15
BR112013011176A2 (pt) 2020-09-01
KR20150020734A (ko) 2015-02-26
CN104800844A (zh) 2015-07-29
PL3111954T3 (pl) 2019-10-31
AU2011325134B2 (en) 2014-10-23
JP6049843B2 (ja) 2016-12-21
IL262559A (en) 2018-12-31
US20230293683A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
FI3757126T3 (fi) Menetelmä nivelreuman hoitamiseksi il-17-antagonistien avulla
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
HRP20180301T1 (hr) Postupci liječenja psorijaze uporabom il-17 antagonista
RU2017134443A (ru) Способ лечения с применением традипитанта
CY1124734T1 (el) Μορφες δοσολογιας αυξητικης ορμονικης μακρας δρασης
MX385543B (es) Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b.
EA201070757A1 (ru) Режим дозирования инъекционных препаратов эфиров палиперидона длительного действия
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
JP2012193216A5 (cg-RX-API-DMAC7.html)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
RU2013121788A (ru) Ингибиторы репликации вич
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201590693A1 (ru) Ингибиторы gdf-8
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
WO2012079093A3 (en) Dosage and administration of bispecific scfv conjugates
FI2683245T4 (fi) Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä
CY1118158T1 (el) Δευτεριωμενα 1-πιπεραζινο-3-φαινυλικα ινδανια για τη θεραπευτικη αντιμετωπιση της σχιζοφρενιας
EA201390950A1 (ru) Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой
EP4424709A3 (en) Dosing regimen for anti-bcma agents
RU2012129839A (ru) Комбинация теобромина с деконгестантом и ее применение для лечения кашля
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi